Philosophe B, Greig P D, Hemming A W, Cattral M S, Wanless I, Rasul I, Baxter N, Taylor B R, Langer B
Hepatobiliary/Pancreatic and Liver Transplantation Services, Department of Surgery, University of Toronto, and The Toronto Hospital, Toronto, Ontario, Canada.
J Gastrointest Surg. 1998 Jan-Feb;2(1):21-7. doi: 10.1016/s1091-255x(98)80099-1.
Liver resection or transplantation offers the best opportunity for cure of hepatocellular carcinoma (HCC). To determine the relative roles for resection and transplantation and to evaluate the patient and tumor characteristics that might predict survival, the records of 125 patients treated for nonfibrolamellar HCC at The Toronto Hospital between 1981 and 1996 were reviewed. No adjuvant chemotherapy or antiviral protocols were used. Resection was the first operation in 67 patients; one underwent re-resection. Sixty patients underwent transplantation including two who had previously had a resection; 40 had known or suspected HCC and 20 had incidental tumors identified in the explanted liver. The incidence of cirrhosis was 49% for resection and 88% for transplantation. The incidence of hepatitis B virus (HBV) was 58% and 33%, respectively. The operative mortality rate for resection was 4.4% (9.4% in cirrhotic and 0 in noncirrhotic patients) and 13.3% for transplantation. The 5-year cumulative recurrence rate was 55% following resection and 20% following transplantation (P <0.001). The 5-year Kaplan-Meier survival rates were 38% for resection and 45% for transplantation-60% for transplanted HBV-negative and 17% for HBV-positive patients (P <0.001). After resection, recurrent HCC accounted for 86% of deaths, whereas recurrent HBV was responsible for 42% of deaths after transplantation. By univariate analysis, following resection, vascular invasion, advanced stage, multiple tumors, and lack of a capsule were predictive of survival; cirrhosis, HBV, age, tumor size, number, and grade were not. By multivariate analysis, only vascular invasion was predictive for resection and HBV for transplantation. Resection and transplantation are complementary methods of treating HCC. With the current organ shortage, resection should be considered first-line treatment. HBV-positive patients with HCC should only undergo transplantation in combination with effective antiviral therapy.
肝切除术或肝移植术为肝细胞癌(HCC)的治愈提供了最佳机会。为了确定切除术和移植术的相对作用,并评估可能预测生存的患者和肿瘤特征,我们回顾了1981年至1996年间在多伦多医院接受非纤维板层型HCC治疗的125例患者的记录。未使用辅助化疗或抗病毒方案。67例患者首次接受了切除术;1例接受了再次切除术。60例患者接受了移植术,其中2例曾接受过切除术;40例患有已知或疑似HCC,20例在移植肝中发现了偶然肿瘤。切除术患者的肝硬化发生率为49%,移植术患者为88%。乙型肝炎病毒(HBV)感染率分别为58%和33%。切除术的手术死亡率为4.4%(肝硬化患者为9.4%,非肝硬化患者为0),移植术为13.3%。切除术后5年累积复发率为55%,移植术后为20%(P<0.001)。切除术后5年的Kaplan-Meier生存率为38%,移植术后为45%——移植的HBV阴性患者为60%,HBV阳性患者为17%(P<0.001)。切除术后,复发性HCC占死亡原因的86%,而移植术后复发性HBV占死亡原因的42%。单因素分析显示,切除术后,血管侵犯、晚期、多发肿瘤和无包膜可预测生存;肝硬化、HBV、年龄、肿瘤大小、数量和分级则不能。多因素分析显示,只有血管侵犯可预测切除术的预后,而HBV可预测移植术的预后。切除术和移植术是治疗HCC的互补方法。鉴于目前器官短缺,切除术应被视为一线治疗方法。HBV阳性的HCC患者仅应在联合有效抗病毒治疗的情况下接受移植术。